Neurocrine Biosciences launches $300M accelerated share repurchase with Goldman Sachs

NEUROCRINE BIOSCIENCES INC

Entered into ASR agreement with Goldman Sachs & Co. to repurchase $300M of common stock.
On Nov 4, 2024, will pay $300M and receive 80% of shares based on Oct 31 closing price.
Final settlement expected in Q1 2025; additional shares or cash adjustments possible per terms.
Repurchase conducted under previously announced $300M board-authorized share repurchase program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.